What is a stock summary page? Click here for an overview.
Business Description
Apellis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US03753U1060
Compare
Compare
Traded in other countries / regions
APLS.USA1JK.Germany Index Membership
Russell 1000Russell 3000Russell 2000 IPO Date
2017-11-09Description
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.88 | |||||
| Equity-to-Asset | 0.26 | |||||
| Debt-to-Equity | 2.06 | |||||
| Debt-to-EBITDA | -3.04 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.99 | |||||
| Beneish M-Score | 18.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 100 | |||||
| 3-Year EBITDA Growth Rate | 47.6 | |||||
| 3-Year EPS without NRI Growth Rate | 39.4 | |||||
| 3-Year FCF Growth Rate | 52.6 | |||||
| 3-Year Book Growth Rate | -3.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 17.73 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.02 | |||||
| 9-Day RSI | 33.23 | |||||
| 14-Day RSI | 34.97 | |||||
| 3-1 Month Momentum % | -19.27 | |||||
| 6-1 Month Momentum % | -12.06 | |||||
| 12-1 Month Momentum % | -51.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.25 | |||||
| Quick Ratio | 3.81 | |||||
| Cash Ratio | 2.22 | |||||
| Days Inventory | 411.05 | |||||
| Days Sales Outstanding | 123.57 | |||||
| Days Payable | 114.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.5 | |||||
| Shareholder Yield % | -9.17 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.93 | |||||
| Operating Margin % | -21.11 | |||||
| Net Margin % | -25.33 | |||||
| FCF Margin % | -11.3 | |||||
| ROE % | -83.06 | |||||
| ROA % | -22.94 | |||||
| ROIC % | -48.63 | |||||
| 3-Year ROIIC % | 164.28 | |||||
| ROC (Joel Greenblatt) % | -60.12 | |||||
| ROCE % | -23.66 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 2967.02 | |||||
| PS Ratio | 3.77 | |||||
| PB Ratio | 12.91 | |||||
| Price-to-Tangible-Book | 12.91 | |||||
| EV-to-EBIT | -19.85 | |||||
| EV-to-Forward-EBIT | -28.03 | |||||
| EV-to-EBITDA | -20.08 | |||||
| EV-to-Forward-EBITDA | -28.22 | |||||
| EV-to-Revenue | 3.97 | |||||
| EV-to-Forward-Revenue | 3.62 | |||||
| EV-to-FCF | -35.16 | |||||
| Price-to-GF-Value | 0.12 | |||||
| Price-to-Net-Current-Asset-Value | 22.42 | |||||
| Earnings Yield (Greenblatt) % | -5.04 | |||||
| FCF Yield % | -2.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:APLS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Apellis Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 781.368 | ||
| EPS (TTM) ($) | -1.59 | ||
| Beta | -0.11 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.25 | ||
| Volatility % | 45.32 | ||
| 14-Day RSI | 34.97 | ||
| 14-Day ATR ($) | 1.079992 | ||
| 20-Day SMA ($) | 24.923 | ||
| 12-1 Month Momentum % | -51.56 | ||
| 52-Week Range ($) | 23.37 - 59.91 | ||
| Shares Outstanding (Mil) | 125.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Apellis Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Apellis Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Apellis Pharmaceuticals Inc Frequently Asked Questions
What is Apellis Pharmaceuticals Inc(APLS)'s stock price today?
The current price of APLS is $23.76. The 52 week high of APLS is $59.91 and 52 week low is $23.37.
When is next earnings date of Apellis Pharmaceuticals Inc(APLS)?
The next earnings date of Apellis Pharmaceuticals Inc(APLS) is 2025-05-07 Est..
Does Apellis Pharmaceuticals Inc(APLS) pay dividends? If so, how much?
Apellis Pharmaceuticals Inc(APLS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers